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Inflammation and oxidative stress at the maternal-fetal interface characterize the placental
dysfunction that underlies the pregnancy disorder preeclampsia. Specialized fetal trophoblasts
directly interact with leukocytes at both sites of the maternal-fetal interface; the uterine wall
decidua; and the placenta. TLR3 has been implicated in the harmful inflammation at thematernal-
fetal interface in preeclampsia, but the cellular involvement in the decidua and placenta has not
been determined. This study aimed to characterize and quantify cell-specific TLR3 expression and
function at the maternal-fetal interface in normal and preeclamptic pregnancies. TLR3 expres-
sion was assessed by immunohistochemistry and quantified by a novel image-based and cell-
specific quantitation method. TLR3 was expressed at the maternal-fetal interface by all decidual
and placental trophoblast types and by maternal and fetal leukocytes. Placental, but not decid-
ual, TLR3 expression was significantly higher in preeclampsia compared to normal pregnancies.
This increase was attributed to placental intravillous tissue and associated with both moderate
and severe placental dysfunction. TLR3 pathway functionality in the decidua and placenta was
confirmed by TLR3 ligand-induced cytokine response, but the TLR3 expression levels did not cor-
relate between the two sites. In conclusion, functional TLR3 was broadly expressed by maternal
and fetal cells at both sites of thematernal-fetal interface and the placental intravillous expression
was increased inpreeclampsia. This suggestsTLR3-mediated inflammatory involvementwith local
regulation at both sites of thematernal-fetal interface in normal and preeclamptic pregnancies.
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1 INTRODUCTION
For a successful pregnancy an excellent collaboration between the
mother and fetus is required. Maternal and fetal cellular crosstalk
occurs at the two sites of the maternal-fetal interface; the maternal
Abbreviations: CD, Cluster of differentiation; CK7, Cytokeratin 7; FGR, Fetal growth restriction; IP-10, IFN-𝛾-induced protein; Poly I:C, Polyinosinic : polycytidylic acid; ROD, Region of
disinterest; sFlt-1, soluble FMS-like tyrosine kinase-1.
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uterine wall decidua and the placenta.1 The fetal cells interacting
with maternal cells at both sites are the specialized trophoblasts.
In the decidua, invasive extravillous trophoblasts directly interact
with tissue resident maternal leukocytes. The placental surface con-
sists of a multinucleated syncytiotrophoblast layer and underlaying
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cytotrophoblasts that cover the fetal intravillous tissue and blood
vessels. The syncytiotrophoblast layer communicates directly with
maternal leukocytes in the intervillous space where maternal blood
is supplied from the uterine arteries. The low-grade inflammation at
the maternal-fetal interface occurring in normal pregnancy is tightly
regulated by local and systemic immune regulatory mechanisms and
the trophoblasts serve as sensors and regulators.2 Imbalance in the
inflammatory response may have drastic impact on the maternal-fetal
crosstalk and contribute to development of inflammatory disorders
such as preeclampsia. Preeclampsia occurs in 2–7%of pregnancies and
is a leading cause of maternal and perinatal mortality and morbidity,
resulting in significant worldwide health challenges.3-6 The disease
is diagnosed with maternal end-stage signs of de novo hypertension
with proteinuria or end-organ involvement after gestational week
20. Preeclampsia most often develops in two stages; first, incomplete
adaption to pregnancy in the uterine wall decidua leads to placental
dysfunction characterized by inflammation, endoplasmic reticulum
stress, and oxidative stress; and later, exaggerated maternal response
to placental stress signals leads tomaternal disease.7
The dysfunctional placenta in preeclampsia propagates both the
local inflammation and the systemic maternal response by produc-
ing increasing amounts of danger signals from damaged placental
tissue.8-10 TLRs have been given an important role in the ongoing
inflammation at the maternal-fetal interface by sensing placental
stress signals and orchestrate production of inflammatory cytokines
and mobilization of innate and adaptive immune responses.11 TLR3
recognizes double-stranded RNA (dsRNA) released from necrotic cells
upon tissue stress or damage or as a viral replication intermediate
associated with viral infection.12,13 Previous research has suggested
a role for TLR3-mediated inflammation at the maternal-fetal inter-
face in normal and preeclamptic pregnancies,14,15 and we have
demonstrated functional placental TLR3 in primary first trimester
trophoblasts.16 TLR3 activation in pregnant mice has been shown to
induce preterm delivery and placental inflammation,14,17,18 and was
involved in induction of hypertension.19 Increased placental TLR3
expression at term has been associated with preeclampsia in a small
study (n = 5),15 whereas a role of TLR3-mediated inflammation in the
decidua still needs to be determined. A comprehensive analysis of cel-
lular expression and functionality of TLR3 across the two sites of the
maternal-fetal interface is missing. This study aimed to characterize
the cell-specific inflammatory involvement of TLR3 at both sites of the
maternal-fetal interface in normal pregnancies and investigate a role
for TLR3 in preeclampsia.
2 MATERIALS AND METHODS
2.1 Patient samples
Women with and without preeclampsia with singleton pregnan-
cies delivering by caesarean sections were recruited at St. Olavs
and Haukeland University Hospitals in Norway between 2002 and
2012. Preeclampsia was defined by persistent hypertension (systolic/
diastolic blood pressure 140/90) and proteinuria (300mg/24 h or≥1+
by dipstick) developing after 20 wk of gestation.20 Women with no
previous history of preeclampsia or the related disorder fetal growth
restriction (FGR) were included as normal pregnant controls. After
delivery, a placental tissue biopsy was taken tangentially from the
central part of the fetal side of the placenta in a standardized man-
ner and a decidual sample was obtained by vacuum suction.21 Both
tissue types were fixed in 10% formalin and paraffin embedded.
Metabolomics profiling of the placental tissue was used to distinguish
pregnancies with normal placental function from pregnancies with
moderate and severe placental dysfunction.22
First trimester placental tissue was collected from women under-
going surgical elective abortion at 7–12 wk of gestation. Tissues were
snap frozen and stored at−80◦Cuntil fixation and paraffin embedding.
Fresh decidual and placental samples from normal pregnant controls
were collected after delivery for immediate isolation of explants.
Informed written consent was obtained from all participants and
the study was approved by the Norwegian Regional Committee for
Research Ethics (REC 2012/1040 and REC 2009/03).
2.2 Immunohistochemistry
A total of 3 µm sections of decidual and placental tissue were incu-
bated overnight at 4◦C with a primary antibody for TLR3 (diluted
1:20 for decidua and 1:19 for placenta, #D10F10 Cell Signalling Tech-
nology, MA, USA). Serial sections were incubated with primary anti-
bodies for the trophoblast marker cytokeratin 7 (CK7) (1:300 for
decidua and 1:800 for placenta, #M7018 Dako, Glostrup, Denmark),
the endothelial cell marker cluster of differentiation 31 (CD31; 1:50,
#M0823 Dako) or CD45 (1:150 for decidua and 1:300 for placenta,
#M0701Dako) for 40min at room temperature. All slideswere further
incubated for 30 min with HRP-labelled polymer (no. K4007; Dako).
DAB+ (1:50, #K4007, Dako) was used as chromogen with two 5 min
incubations and slides were counterstained with hematoxylin. CK7
decidual slides were double stained with smooth muscle actin anti-
bodies (1:300, #M0851 Dako) with EnVision G|2 Doublestain System
Rabbit/Mouse (DAB+/Permanent Red) Kit system (#K5361, Dako).
Hematoxylin-eosin-saffron and negative isotype control staining was
included (1:190, TLR3; Rabbit DA1E mAb #3900, Cell Signalling Tech-
nology) (Supporting Information Fig. S1).
2.3 Explant stimulation
Fresh placentas from normal pregnancies were processed within
1.5 h of delivery and cotyledons isolated from the central part of
the placenta. Decidual tissue was carefully dissected, washed in PBS
supplementedwith penicillin-streptomycin, and cut in pieces of similar
weight (24.2 mg ± 2.1 wet weight). Placental chorionic villi were
isolated by mechanically removing the fetal membrane and decidua,
washed in PBS supplemented with penicillin-streptomycin, and cut in
pieces (22.4 mg ± 2.6 wet weight). All explants were cultured in Ham’s
F12/DMEM medium supplemented with 10% FBS and 100 mg/ml
penicillin-streptomycin (all from Sigma-Aldrich, St. Louis, MO, USA)
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and incubated overnight at 8% O2, 5% CO2 and 37
◦C.23 Culture
medium was replaced with 250 µl fresh medium with or without
TLR3 ligand, either 2–50 µg/ml polyinosinic : polycytidylic acid (poly
I:C, high molecular weight, #tlrl-pic, Invivogen, San Diego, CA, USA)
or Riboxxol (dsRNA duplex, #63231-63-0, Riboxx GmbH, Radebeul,
Germany). Supernatants were collected after 24 h and stored at
−80◦C. Cell viability was assessed by lactate dehydrogenase (LDH)
cytotoxicity assay (#04744926001, Roche, Indianapolis, IN, USA).
For further analysis, six technical replicates for each experimental
condition were combined. IL-6, IL-8, IFN-𝛾-inducible protein-10
(IP-10), and soluble FMS-like tyrosine kinase-1 (sFlt-1) were mea-
sured in duplicate in supernatants by quantitative sandwich ELISA
(#DY206, #DY208, #DY266, #DY321B; R&D Systems, Minneapolis,
MN, USA).
2.4 Quantitative protein expression analysis
To ensure a representative analysis, large decidual tissue section
scans consisting of 4–81 bright field TIFF images for each donor
(20× magnification) were obtained by the EVOS FL Auto Imaging
System (Thermo Fisher Scientific, Waltham, MA, USA), with defined
microscope settings. A customized ImageJ (ImageJ2)
24,25 script was
used to perform background correction (Image calculator: Difference
(img1 = |img1 − img2|) and tile stitching (grid/collection stitching
plugin).26 Decidual TLR3 expression levels were quantified using cus-
tomizedMATLAB scripts (version 2017b, theMathWorks, Inc., Natick,
MA, USA) developed for identification and automatic quantification
of staining density and intensity. A mask of patches (1325 x 1325 µm)
defining trophoblasts, maternal leukocytes, and other maternal tissue
was created for each decidua sample by using the serial tissue section
scans stained for trophoblasts (CK7+) and leukocytes (CD45+).
Muscle cells, placental tissue, blood vessels, and glands were excluded
from analyses by manually defining regions of disinterest (RODs).
The created masks were used to relate TLR3 expression levels to
trophoblasts and maternal leukocytes in the spatially aligned images.
The “expression density” of CK7, CD45, and TLR3 was calculated
as the total number of positive stained pixels divided by the total
amount of tissue pixels included in the analysis, to account for varying
amounts of tissue between the samples. The TLR3 “expression inten-
sity” was calculated as the average staining intensity of all positive
patches. Leukocytes and trophoblasts were automatically counted and
expressed as total number divided by the total area of tissue (mm2). A
color deconvolution algorithm based on DAB specific red green blue
(RGB) absorption was used for quantification of protein expression.27
Large placental tissue section scans consisting of 4–25 bright field
TIFF images for each donor (20× magnification) were taken, back-
ground corrected and tile-stitched, like for decidua. A customized
MATLAB script was used to quantify TLR3 expression levels. Stem
villi, decidual tissue, and tissue with poor aberrant morphology were
excluded as RODs. A binary mask was created by segmentation based
onRGBcolor values using the color threshold app inMATLAB, to select
CK7, CD45, or TLR3 positive pixels. The expression density of CK7,
CD45, and TLR3were calculated as described for decidua. The expres-
sion intensity of TLR3wasmeasured as the average intensity of all pix-
els in the binarymask.
The TLR3 expression in the placental syncytiotrophoblast layer and
cytotrophoblasts (n = 6–40 per placental sample) of mature villi was
analyzed in three selected bright field images (20x) obtained by an
Eclipse E400 microscope and DS-Fi1 camera (Nikon, Tokyo, Japan)
with defined settings. The syncytiotrophoblast layer was selected in
a binary layer by manually setting a threshold for CK7+ staining
using NIS-Elements BR 4.0 software. Cytotrophoblast were manually
selected based on morphology. The TLR3 intensity values of the syn-
cytiotrophoblast and cytotrophoblasts were measured as grey-level
intensity values ranging from 0 (absence of color, black) to 255 (pres-
enceof all colors,white) after conversion fromRGBtograyscale images
and calculated as themean of positive pixels in selected areas.
All analyses were done with pregnancy outcome blinded for
the observer.
2.5 Statistical analyses
Statistical analyses were performed in SPSS (IBM SPSS Statistics 25)
and GraphPad Prism (Prism7). Clinical characteristics of study objects
in the two diagnostic groups were compared by unpaired t-test or
Mann-Whitney test. Cytokine measurements in explant studies were
analyzed by Kruskal-Wallis with Dunn’s multiple comparison post hoc
test. Immunohistochemistry data were analyzed by a linear mixed
model.Decidual TLR3expression levelswere comparedbetweenstudy
groups using a linear mixed model with recruitment location, study
group, and the trophoblast and leukocyte densities implemented as
fixed effects. Subject combinations and interceptwere included as ran-
domeffects. Placental TLR3expression levelswere comparedbetween
study groups using a linear mixedmodel with recruitment location and
study group as fixed effects. Subject combinations and intercept were
included as random effects. Correlations between variables were per-
formedbycalculatingPearson’s correlation coefficient.Alpha levelwas
set to 0.05.
2.6 Online supplemental material
Supporting Information Figure S1 demonstrates negative isotype con-
trol staining for TLR3 of decidual tissue at delivery, first trimester pla-
cental tissue, and placental tissue at delivery. Supporting Information
Figures S2 and S3 demonstrate immunohistochemical staining of TLR3
expression in decidual (Fig. S2) and placental tissue (Fig. S3) at delivery
fromnormal pregnancies andpreeclamptic pregnancieswithmoderate
or severe placental dysfunction.
3 RESULTS
3.1 Clinical characteristics of the study group
Of the 108 pregnancies included for immunohistochemistry (Table 1),
decidual biopsies from42normal and48preeclamptic pregnancies and
placental biopsies from 13 normal and 28 preeclamptic pregnancies
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(n= 48) (n= 60)
Baseline characteristics
Maternal age, years 31.5 (±5.3) 29.5 (±5.3)
Primiparas, n (%)
b
8 (17) 36 (60)
BMI
c
24.8 (±3.9) 26.5 (±5.2)








72.4 (±7.7) 98.7 (±11.4)*








623 (±102) 340 (±138)*
Fetal birth weight, g 3431 (±325) 1586 (±655)*
Gestational age, weeks
e
39 (±0.7) 32 (±3.7)*
BMI, bodymass index; n.a., not applicable.
Continuous variables listed as means (±SD) assessed for differences
between groups by unpaired t-test orMann-Whitney test. Categorical vari-
ables listed as number (percentage in column).
aSix of the pregnancies were diagnosed with superimposed preeclampsia
and 38were diagnosedwith fetal growth restriction (FGR).
bInformationmissing from one pregnancy
cMaternal BMI in first trimester. Information missing from four pregnan-
cies.
dBlood pressure from last healthcare visit before delivery.
eInformationmissing from two pregnancies.
fPreeclampsiawas sub-phenotyped as severe if diagnosedwith oneormore
severe features.49
gInformationmissing from 12 pregnancies.
∗P< 0.0001 vs. normal pregnancies.
were available. Both sites of the maternal-fetal interface were avail-
able from 7 normal and 16 preeclamptic pregnancies. Maternal blood
pressure was higher and gestational age at delivery and fetal and pla-
cental weight were lower in preeclamptic pregnancies compared to
normal pregnancies, as expected (Table 1).
Theaveragegestational ageof the three included first trimester pla-
centas was 10 wk (range 7–12 wk). Only information on maternal age
(range 25–39 yr) and gestational age (range 267–277 d) was available
for the six fresh term placentas included for explant stimulation.
3.2 Functional expression of TLR3 at the
maternal-fetal interface of normal pregnancies
TLR3 was expressed at both sites of the maternal-fetal interface. In
the decidua a heterogeneous pattern of TLR3 expressionwas detected
with strong expression in maternal leukocytes and weaker expres-
sion in trophoblasts and decidual stromal cells (Fig. 1). Placental TLR3
was expressed in the syncytiotrophoblast layer and cytotrophoblasts
in both early (Fig. 1) and late pregnancies (Fig. 2A–D). A placental
TLR3 expression at delivery was further observed in leukocytes, and
aweaker expression was found in endothelial cells.
The decidual cell-specific TLR3 expression intensity and den-
sity was comparable between trophoblasts, maternal leukocytes,
and maternal tissue (data not shown). Cell-specific quantification
of the placental TLR3 expression intensity revealed comparable
and highly correlated expression levels (R2 = 0.9 P < 0.001)
between the multinucleated syncytiotrophoblast and the underlying
cytotrophoblasts (Fig. 2E).
When comparing the TLR3 expression at the two aligned sites of
the maternal-fetal interface in normal pregnancies, neither the TLR3
expression intensity nor density showed any correlation between
decidual and placental tissue (data not shown).
Explant stimulation with the TLR3 ligand poly I:C led to sig-
nificant dose-dependent decidual increase of IP-10 (Fig. 3A) and
placental increase of IL-6 and IP-10 (P < 0.05) (Fig. 3B), whereas the
production of IL-8 and sFlt-1 was not affected in either tissue (Fig. 3A,
B). The synthetic TLR3 ligand Riboxxol did not induce significant
increase of cytokines in decidual explants (Fig. 3C) but led to signifi-
cant increase of IL-6 production in placental explants (Fig. 3D). Overall,
the cytokine responses were lower in decidual than in placental
explants (Fig. 3A vs. B and Fig. 3C vs. D). LDH viability assay confirmed
that the stimuli had no toxic effect on cell viability (data not shown).
3.3 Expression of TLR3 at thematernal-fetal
interface in preeclampsia
The same cell types expressed TLR3 at the maternal-fetal interface
in preeclampsia as in normal pregnancies (Supporting Information
Figs. S2 and S3). The overall decidual TLR3 expression intensity and
density did not differ between normal and preeclamptic pregnancies
(Fig. 4A, B, respectively). Accordingly, this was also true for the
sub-analysis of TLR3 expression intensity in maternal cells and tro-
phoblasts (Fig. 4C, D). The overall placental TLR3 expression intensity
was significantly increased in preeclamptic compared to normal preg-
nancies (Fig. 4E, P < 0.01), whereas no differences in TLR3 expression
density was detected (Fig. 4F). The differences in TLR3 expression
intensity could not be attributed to TLR3 expression in syncytiotro-
phoblast (Fig. 4G) or cytotrophoblasts (Fig. 4H). Neither TLR3 expres-
sion intensity nor density showed any correlation between decidual
and placental tissue from preeclamptic pregnancies (data not shown).
3.4 TLR3 expression at thematernal-fetal interface
related to the grade of placental dysfunction and
leukocyte density
To further assess the TLR3 expression intensity in preeclamptic preg-
nancies, the grade of placental dysfunction22 was taken into account
(Fig. 4I, J). The TLR3 expression intensity in the placenta (Fig. 4J), but
not decidua (Fig. 4I), was increased in preeclamptic pregnancies with
both moderate and severe placental dysfunction as compared to nor-
mal pregnancies with normal placental function.
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F IGURE 1 Decidual and first trimester placental TLR3 expression. Immunohistochemical staining of decidual tissue at delivery (A–D) and first
trimester placental tissue (E–H) for trophoblasts (CK7) (A, E), endothelial cells (CD31) (B, F), and leukocytes (CD45) (C, G). TLR3 expression (D, H)
in trophoblasts is indicated with a black arrow and in leukocytes with an open arrow. Decidual tissue from a normal pregnancy at gestational age
39+ 5wk. First trimester placental tissue from gestational age 11+ 5wk.Magnification 20×. Scale bar indicates 200 µm
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F IGURE 2 Placental TLR3expression at delivery. Immunohistochemical staining of placental tissue for trophoblasts (CK7) (A), endothelial cells
(CD31) (B), and leukocytes (CD45) (C). TLR3 expression (D) in the syncytiotrophoblast layer is indicated with a black arrow and a cytotrophoblast
with an open arrow. Normal pregnancy at gestational age 38 + 6 wk. Magnification 20×. Scale bar indicates 200 µm. TLR3 expression intensity in
the placenta at delivery of normal pregnancies (n = 12) was highly correlated between the syncytiotrophoblast and cytotrophoblasts (R2 = 0.93,
P< 0.001) (E)
The decidual and placental leukocyte density was quantified (Fig. 5)
and related to TLR3 expression levels (Fig. 4). The leukocyte density
was significantly higher in the decidua than in the placenta (P < 0.001)
and showed no correlation between decidual and placental tissues.
The number of decidual leukocytes did not differ between normal
and preeclamptic pregnancies (Fig. 5A), whereas fewer placental
leukocytes were observed in preeclamptic vs. normal pregnancies
(Fig. 5B). We found no correlation between the leukocyte density
(Fig. 5) and either the decidual (Fig. 4A, B) or placental (Fig. 4E, F) TLR3
expression intensity or density in normal or preeclamptic pregnancies.
4 DISCUSSION
This study revealed functional and cell-specific TLR3 expression at
the two sites of the maternal-fetal interface involving both maternal
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F IGURE 3 TLR3 activated cytokine response in cultured explants.Decidual (A, C) and placental (B, D) explants were stimulated for 24 h with
0–50 µg/ml TLR3 ligand Poly I:C (A, B) or Riboxxol (C, D). Levels of IL-6 and IL-8 (n = 5 for Poly I:C, n = 3 for Riboxxol), and IP-10 and soluble FMS-
like tyrosine kinase-1 (sFlt-1; n = 3) were quantified in the supernatant by ELISA. Fold changes relative to unstimulated explants are presented as
mean± SD of three or five replicates. *P< 0.05 vs. unstimulated
and fetal cells. TLR3 was expressed by all decidual and placental tro-
phoblast types and by maternal and fetal leukocytes in normal and
preeclamptic pregnancies, but the decidual-placental TLR3 expression
levels did not correlate. Preeclampsia was associated with increased
intravillous TLR3 expression. This suggests TLR3 involvement in the
inflammation occurring at the maternal-fetal interface in normal preg-
nancies, and an added role for TLR3 in the harmful inflammation
and placental dysfunction in preeclampsia, located to the intravillous
placental structures and not to the direct maternal-fetal interaction
sites. These findings were achieved by a novel quantitative image-
based method for cell-specific assessment of protein expression in
complex tissues.
The overall understanding of immune regulation at the two sites of
the maternal-fetal interface is hampered by the lack of knowledge of
pathologic processes in theuterinewall decidua. TLR3geneexpression
in first trimester decidua28 and functional TLR3 expression in isolated
decidual macrophages and natural killer cells have been reported,29
but this is the first quantitative characterization of cell-specific TLR3
protein expression in decidua. For placental TLR3 expression, support-
ing findings have been reported in early pregnancy and at delivery.30,31
The decidua and placenta have important immunoregulatory functions
throughout pregnancy and the strong TLR3 expression in maternal
and fetal cells confirms an active role for TLR3 in the ongoing inflam-
mation in normal pregnancy and the dynamic maternal and fetal
cell crosstalk. This importance of TLR3 was underlined by functional
pathway confirmation in both tissues. This maternal-fetal crosstalk in
the decidua in late stages of pregnancy is only beginning to be charac-
terized, but its relevance is strongly supported by the shift in decidual
immune cell compositions observed in late pregnancy.32,33 The lack
of correlation for TLR3 expression between the decidua and placenta
points to divergent immune regulation of TLR3 at the two sites of
the maternal-fetal interface, possibly reflecting a decidual influence
from maternal systemic danger signals and placental influence from
placental or fetal dysregulated processes and danger signals.
The increased placental TLR3 expression in preeclampsia could not
be attributed to trophoblasts in this study and this finding contrasts
an existing small study.15 Interestingly, the placental TLR3 expres-
sion pattern differed from TLR4, as we previously reported increased
expression of TLR4 located to the syncytiotrophoblast in the same
preeclamptic pregnancies.8 This suggests that TLRs are differentially
regulated at thematernal-fetal interface in preeclampsia and strength-
ens the importance of addressing distinct inflammatory pathways.
The intravillous fetal structures consist of stromal cells, endothelial
cells, and leukocytes. The observed increase in the cellular expres-
sion pattern of TLR3, combined with supporting literature,15,34 sug-
gests a role for the specialized placental macrophages, the Hofbauer
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F IGURE 4 Overall and cell-specific TLR3
expression in the decidua and placenta in
normal and preeclamptic pregnancies. Over-
all decidual (A, B) and placental (E, F) TLR3
expression intensity (A, E) and density (B, F) is
shown. Cell-specific TLR3 expression intensity
inmaternal cells (C) and trophoblasts (CK7+) (D)
is shown in decidual tissue from normal (n = 42)
and preeclamptic (n = 48) pregnancies at deliv-
ery. TLR3 expression intensity in maternal cells
was calculated from tissue areas without tro-
phoblasts (CK7-) and TLR3 expression intensity
in decidual trophoblasts was calculated from tis-
sue areas with >50% trophoblast density. Pla-
cental cell-specific TLR3 expression intensity in
the multinucleated syncytiotrophoblast (G) and
cytotrophoblasts (H) was analyzed in normal
(n = 13 for syncytiotrophoblast and n = 12
for cytotrophoblasts) and preeclamptic (n = 28)
pregnancies at delivery. Overall TLR3 expres-
sion intensity was determined in the decidua
(I) from normal pregnancies with normal pla-
centas (n = 27), preeclamptic pregnancies with
moderate placental dysfunction (n = 28) and
preeclamptic pregnancies with severe placen-
tal dysfunction (n = 16); and in the placenta (J)
from normal pregnancies with normal placentas
(n= 9), preeclamptic pregnancieswithmoderate
placental dysfunction (n = 21) and preeclamptic
pregnancies with severe placental dysfunction
(n= 7). *P< 0.05, **P< 0.01, and ***P= 0.001 vs.
normal pregnancies
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F IGURE 5 Leukocyte density in the decidua and placenta in normal and preeclamptic pregnancies. Leukocyte density (CD45+) in decidual (A)
and placental (B) samples from normal (n = 41 and n = 13, respectively) and preeclamptic (n = 43 and n = 28, respectively) pregnancies at delivery
was calculated as total positive CD45 pixels dived by the total area. **P= 0.01 vs. normal pregnancies
cells, but this needs further characterization. The TLR3 expression in
Hofbauer cells observed in early pregnancy is supported by others,31
and suggests importance for placental immune activity throughout
pregnancy. The increased intravillous TLR3 expression in preeclamp-
sia cannot be explained by a change in leukocyte numbers, because
preeclampsiawasassociatedwith reduced leukocytedensity, anobser-
vation supported by others.35 This reduction in important immune
cells in preeclampsia is thought to negatively influence the placen-
tal homeostasis.36,37 Stromal cells and endothelial cells could also be
responsible for the observed increase in intravillous TLR3 expression
as supported by a small study (n = 5) from Pineda et al.15 Villous
mesenchymal stromal cells have been shown to produce more inflam-
matory cytokines, chemokines, and growth factors in preeclampsia
compared to normal pregnancies and this may contribute to placen-
tal dysfunction and the exacerbated inflammatory response.38 Pla-
cental angiogenesis is impaired in preeclampsia and TLR3 activation
in mice has been shown to cause endothelial dysfunction comparable
to in women with preeclampsia.14 However, the biologic significance
of TLR3 expression in these cells has not yet been determined. The
TLR3 expression in cells involved in the direct maternal-fetal interac-
tion in the decidua and placenta was not influenced in preeclampsia.
This suggests that the role of TLR3 in maternal-fetal communication is
restricted to the physiologic inflammation of normal pregnancies and
not affected by the placental dysfunction in preeclampsia.
In addition to being activated by dsRNA from viral infections,39
TLR3 may be activated by mRNA released from necrotic cells or
noncoding RNA fromultraviolet B-irradiated cells to generate a robust
immune response.13,40 Thedelivery andexposureof theseendogenous
ligands to the endosome-restricted TLR3 is still poorly understood.
The natural activators of TLR3 during pregnancy could be derived
from shed trophoblast debris, exosomes, and danger signals, which are
released from placental tissue locally and to the maternal circulation
as part of the low-grade inflammation in normal pregnancies, and
this shedding is markedly increased in preeclampsia.41 Preeclampsia
is further associated with apoptosis of villous cytotrophoblasts and
the potential local release of dsRNA might explain why TLR3 was
increased only in intravillous cells.42 Other sources for naturally avail-
able danger signals may potentially be the placental microbiome43
adding potential TLR3 ligands at thematernal-fetal interface.We used
high molecular weight poly I:C and Riboxxol to activate TLR3, but the
activation of other cytosolic receptors such as retinoic acid inducible
gene 1 and melanoma differentiation-associated protein 544 may
possibly have contributed to the cytokine response.45 The efficiency
of TLR3 activation by different types of dsRNA may be influenced by
their size as smaller dsRNAmay penetrate the cells more efficiently.46
Accordingly, the smaller Riboxxol (50 bp) induced a higher cytokine
response in stimulated explants compared to the high molecular
weight poly I:C (1.5–8 kb).
The heterogeneous disorder preeclampsia consists of distinct sub-
types that go beyond the current diagnostic measures.22,47 Different
ongoing pathologic processes at the maternal-fetal interface might
give the same clinical symptoms in the preeclamptic mother and a
better classification of the disorder taking placenta dysfunction into
account would lead to improved understanding, screening, and treat-
ment of the disease. Approximate subgroups such as preeclampsia
with early or late onset, and with and without FGR are often used
and increasing evidence points to divergent roles for inflammatory
activation in distinct phenotypes.48 The increased placental TLR3
expression associated with preeclampsia was not affected by FGR
or superimposed preeclampsia, but with both moderate and severe
placental dysfunction.22 This shows that the regulation of placental
TLR3 holds true for preeclamptic pregnancies directly affected by
a dysfunctional placenta and therefore possess disturbances of the
physiologic processes occurring at thematernal-fetal interface.
182 GIERMAN ET AL.
In summary, functional TLR3 was broadly expressed by maternal
and fetal cells at both sites of the maternal-fetal interface and the
placental intravillous TLR3 expression was increased in preeclampsia.
Our findings suggest that TLR3 is actively involved in the low-grade
inflammation characterizing maternal-fetal interaction of normal
pregnancies, with local regulation in the decidua and placenta. TLR3
is shown to play a role in the placental dysfunction in preeclampsia
located to intravillous tissue and not to the direct maternal-fetal
communication. This study underlines the importance of detailing the
regulation of cell-specific pathologic processes at the maternal-fetal
interface formorewell-funded understanding of disease development.
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